1. Home
  2. CDLX vs AEON Comparison

CDLX vs AEON Comparison

Compare CDLX & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardlytics Inc.

CDLX

Cardlytics Inc.

HOLD

Current Price

$1.98

Market Cap

12.5M

Sector

Technology

ML Signal

HOLD

Logo AEON Biopharma Inc.

AEON

AEON Biopharma Inc.

SELL

Current Price

$0.24

Market Cap

13.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CDLX
AEON
Founded
2008
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
13.0M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
CDLX
AEON
Price
$1.98
$0.24
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
★ $6.00
$1.82
AVG Volume (30 Days)
57.8K
★ 1.3M
Earning Date
11-04-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 50.13
N/A
EPS
N/A
★ N/A
Revenue
★ $233,273,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.25
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.55
$0.18
52 Week High
$6.40
$1.45

Technical Indicators

Market Signals
Indicator
CDLX
AEON
Relative Strength Index (RSI) 25.92 42.41
Support Level $1.83 $0.24
Resistance Level $4.42 $0.33
Average True Range (ATR) 0.28 0.03
MACD -0.04 -0.00
Stochastic Oscillator 11.01 12.20

Price Performance

Historical Comparison
CDLX
AEON

About CDLX Cardlytics Inc.

Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.

About AEON AEON Biopharma Inc.

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.

Share on Social Networks: